For this understudied population, the findings may offer some reassurance as apixaban is already the most prescribed OAC in the general population of the U.S. and in people with H ...

Purpose The pharmacology, pharmacokinetics, efficacy, and safety of apixaban are reviewed. Summary Apixaban is an oral, direct, selective factor Xa inhibitor with a rapid onset of action.

New data from a clinical trial suggest that apixaban, an anticoagulant that’s widely been prescribed to promote recovery in patients with severe cases of COVID-19, doesn’t offer any discernable ...

Taho Pharmaceuticals’s apixaban-based oral dissolving strips were discovered to be a bioequivalent of Pfizer and Bristol-Myers Squibb’s (BMS) Eliquis in a Phase II trial. The randomised open ...

Further trials comparing aspirin with newer anticoagulants (dabigatran, apixaban and rivaroxaban) are necessary to assess the role of each agent in stroke prevention in patients with AF.

The researchers found that apixaban had similar rates of major bleeding and intracranial hemorrhage compared with aspirin (risk differences, 0.0 [95% confidence interval, −1.3 to 2.6] and −0.2 ...

Apixaban is an anticoagulant, which is used for reducing the risk of strokes and blood clots in patients with atrial fibrillation who have no problems with their heart valve (nonvalvular atrial ...

Venous thromboembolism, comprising pulmonary embolism and deep vein thrombosis, is a common disease with considerable mortality and morbidity, such as post-thrombotic and post-pulmonary-embolism ...